Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Antibe Therapeutics Inc.

Antibe Announces Appointment of Receiver
From Antibe Therapeutics Inc.
Via Business Wire
Tickers TSX:ATE
Antibe Provides Update on CCAA Proceedings
From Antibe Therapeutics Inc.
Via Business Wire
Tickers TSX:ATE
Antibe Announces TSX Delisting Review
From Antibe Therapeutics Inc.
Via Business Wire
Tickers TSX:ATE
Antibe Announces Granting of Initial Order Under Companies' Creditors Arrangement Act
From Antibe Therapeutics Inc.
Via Business Wire
Tickers ATBPF TSX:ATE
Antibe to File an Application for an Initial Order Under Companies' Creditors Arrangement Act
From Antibe Therapeutics Inc.
Via Business Wire
Tickers ATBPF TSX:ATE
Antibe Announces FDA Clinical Hold on Otenaproxesul and Legal Action by Nuance
From Antibe Therapeutics Inc.
Via Business Wire
Tickers ATBPF TSX:ATE
Antibe to Present Otenaproxesul PK/PD Results at the ASRA Pain Medicine Meeting
From Antibe Therapeutics Inc.
Via Business Wire
Tickers ATBPF TSX:ATE
Antibe to Present Otenaproxesul PK/PD Results at the American Academy of Pain Medicine Meeting
From Antibe Therapeutics Inc.
Via Business Wire
Tickers ATBPF TSX:ATE
Antibe Announces Unfavorable Decision in Arbitration With Nuance Pharma
From Antibe Therapeutics Inc.
Via Business Wire
Tickers ATBPF TSX:ATE
Antibe Reports Q3 2024 Interim Financial and Operating Results
From Antibe Therapeutics Inc.
Via Business Wire
Tickers ATBPF TSX:ATE
Antibe Extends Early Warrant Exercise Incentive Program
From Antibe Therapeutics Inc.
Via Business Wire
Tickers ATBPF TSX:ATE
Antibe Announces Early Warrant Exercise Incentive Program
From Antibe Therapeutics Inc.
Via Business Wire
Tickers ATBPF TSX:ATE
Antibe Therapeutics Announces Amendment to Warrant Terms
From Antibe Therapeutics Inc.
Via Business Wire
Tickers ATBPF TSX:ATE
Antibe Reports Q2 2024 Interim Financial and Operating Results
From Antibe Therapeutics Inc.
Via Business Wire
Tickers ATBPF TSX:ATE
Antibe Reports PK Results of First Clinical Study of Otenaproxesul’s New Formulation
From Antibe Therapeutics Inc.
Via Business Wire
Tickers ATBPF TSX:ATE
Antibe Completes First Clinical Study of Otenaproxesul’s New Formulation
From Antibe Therapeutics Inc.
Via Business Wire
Tickers ATBPF TSX:ATE
Antibe Initiates First Clinical Study of Otenaproxesul’s New Formulation
From Antibe Therapeutics Inc.
Via Business Wire
Tickers ATBPF TSX:ATE
Antibe Receives Approval to Initiate PK/PD Study of Otenaproxesul
From Antibe Therapeutics Inc.
Via Business Wire
Tickers ATBPF TSX:ATE
Antibe Announces Results of 2023 Annual Meeting
From Antibe Therapeutics Inc.
Via Business Wire
Tickers ATBPF TSX:ATE
Antibe Reports Q1 2024 Interim Financial and Operating Results
From Antibe Therapeutics Inc.
Via Business Wire
Tickers ATBPF TSX:ATE
Antibe Reports 2023 Year-End Results and Business Highlights
From Antibe Therapeutics Inc.
Via Business Wire
Tickers ATBPF TSX:ATE
Antibe’s Chief Medical Officer to Present at the 2023 Precision in Clinical Trials Summit
From Antibe Therapeutics Inc.
Via Business Wire
Tickers ATBPF TSX:ATE
Antibe to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference
From Antibe Therapeutics Inc.
Via Business Wire
Tickers ATBPF TSX:ATE
Antibe Provides April 2023 Corporate Update
From Antibe Therapeutics Inc.
Via Business Wire
Tickers ATBPF TSX:ATE
Antibe Reports Q3 2023 Interim Financial and Operating Results
From Antibe Therapeutics Inc.
Via Business Wire
Tickers ATBPF TSX:ATE
Antibe Reports Q2 2023 Interim Financial and Operating Results
From Antibe Therapeutics Inc.
Via Business Wire
Tickers ATBPF TSX:ATE
Antibe Closes Previously Announced Strategic Sale of Citagenix Subsidiary
From Antibe Therapeutics Inc.
Via Business Wire
Tickers ATBPF TSX:ATE
Antibe Provides Development Update for Otenaproxesul
From Antibe Therapeutics Inc.
Via Business Wire
Tickers ATBPF TSX:ATE
Antibe Announces Results of 2022 Annual Meeting
From Antibe Therapeutics Inc.
Via Business Wire
Tickers ATBPF TSX:ATE
Antibe Academic Collaborator to Present Clinical Data at PAINWeek 2022
From Antibe Therapeutics Inc.
Via Business Wire
Tickers ATBPF TSX:ATE
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.